

The logo for Nicholas, featuring the word "Nicholas" in white text on a red triangular background.

## **NPIL Research & Development Limited commences Phase I trials on new molecule for metabolic disorders in Europe**

**NPIL Research & Development Limited (NRDL), recently demerged from Nicholas Piramal India Limited (NPIL), has commenced Phase I studies of a new experimental drug molecule, P1201-07, in The Netherlands.**

**The Company had submitted the Clinical Trial Application (CTA) for P1201-07 to the Central Committee on Research Involving Human Subjects (CCMO), the regulatory authority of The Netherlands, and the Independent Ethics Committee of the foundation Evaluation Of Ethics in Biomedical Research (BEBO), Assen, The Netherlands. Both these bodies have approved the Company's application to initiate the Phase I study of P1201-07.**

**P1201-07 is an in-licensed compound from Eli Lilly & Co. (USA) and is being developed for metabolic disorders.**

**“This is our fourth new drug to enter the clinic and the first from the research collaboration with pharma major Eli Lilly. The drug development timeline is on schedule. We in-licensed this molecule from Lilly only in January 2007, and it has gone to the clinic in just a year”, said Dr Swati Piramal, Director – Strategic Alliances & Communications, NPIL.**

**About NPIL Research & Development Limited:** NPIL Research & Development Limited (NRDL) is an independent Company that was recently demerged from Nicholas Piramal India Limited (NPIL). NRDL was formerly the NCE R&D division of NPIL. The Company has R&D capabilities in Custom Chemical Synthesis, Process Innovation, NDDS and Basic Research. NRDL has state-of-the-art R&D laboratories built over 200,000 square-feet of space and over 300 scientists engaged in world-class drug discovery research and development. NRDL is focused on four therapeutic areas – Cancer, Diabetes, Inflammation and Infectious Diseases – with a pipeline of nine synthetic chemical compounds in pre-clinical development. NRDL's lead chemical compound, a Cdk-4 inhibitor, is currently Phase I/II trials for Multiple Myeloma. NRDL also has three phyto-pharmaceutical candidates in clinical trials for Rheumatoid Arthritis, Infectious Disease and Cancer.

**About Nicholas Piramal India Limited:** Nicholas Piramal India Limited (NPIL) is one of India's largest pharmaceutical companies with a growth track record of above 30% CAGR since 1988. The Company is currently ranked 4th in the Indian market with a diverse product portfolio spanning nine therapeutic areas. NPIL had consolidated Revenues of Rs. 24.7 billion in 2006-07. It has world-class USFDA-approved formulations and API facilities without any 483s. NPIL has a long track record of successful collaboration with innovator companies. Since 2003, the Company has made significant investments to become a global custom manufacturing organisation (CMO) for large and medium-sized innovator companies. NPIL is listed in India on the Bombay Stock Exchange and the National Stock Exchange.

**Forward-looking statements:** This news release may contain forward-looking statements that are based on the Company's current beliefs and assumptions and on information currently available to its management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result of these risks, uncertainties and other factors, readers are cautioned not to place undue reliance on any forward-looking statements included in this press release. These forward-looking statements represent beliefs and assumptions only as of the date of this news release, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.

For further information, please contact:

**Sherin Khullar**

Chief Manager

Corporate Communications

Nicholas Piramal India Limited  
Nicholas Piramal Tower  
Ganpatrao Kadam Marg, Lower Parel  
Mumbai 400 013

Tel. (Board): +91-22-30466666

Tel. (Direct): +91-22-30467884

E-mail: [sherin.khullar@nicholaspiramal.co.in](mailto:sherin.khullar@nicholaspiramal.co.in)

URL: [www.nicholaspiramal.com](http://www.nicholaspiramal.com)